Haya Therapeutics: Closes CHF 18M Funding

Haya Therapeutics Closes CHF 18M Funding

• Haya Therapeutics, a Lausanne, Switzerland-based company which develops precision medicines that target tissue and cell-specific long non-coding RNAs, closed  a CHF18M funding round
• The round was led by Broadview Ventures, with participation from Apollo Health Ventures, Bernina BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator
• The company intends to use the funds to advance the discovery and development of innovative organ and cell-selective therapeutics
• The company develops precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs)
• Haya is preparing to initiate clinical trials with its Wisper targeting candidate in non-obstructive hypertrophic cardiomyopathy, an orphan indication with limited treatment options
• The company secured an exclusive license from CHUV for the Wisper asset